Ayala Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 48.07 million compared to USD 38.01 million a year ago. Basic loss per share from continuing operations was USD 7.99.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6431 USD | -3.29% | +19.09% | -3.58% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.58% | 27.42M | |
+0.67% | 42.4B | |
+44.30% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- ADXS Stock
- News Ayala Pharmaceuticals, Inc.
- Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023